The Technical Analyst
Select Language :

Statera Biopharma, Inc. [STAB]
- Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Exchange: ->Biotechnology ->Healthcare

Last updated: 27 Oct 2021 @ 03:26 am

Statera Biopharma, Inc. is listed at the NASDAQ Exchange

0.87% $3.48


FUNDAMENTALS
MarketCap: 115.25 mill
EPS: -0.533
P/E: 0.000
Earnings Date: N/A
SharesOutstanding: 33.12 mill
Avg Daily Volume: 0.204 mill

Insider Trading

Date Person Action Amount type
2021-09-28 Markvicka Taunia Buy 100 000 Common Stock, par value $0.005 per share
2021-09-09 Verny Lea Buy 60 000 Common Stock, par value $0.005 per share
2021-09-09 Barbarick Steve K Buy 60 000 Common Stock, par value $0.005 per share
2021-07-27 Selsky Clifford Buy 101 579 Common Stock, par value $0.005 per share
2021-07-27 Mcavoy Cozette M. Buy 60 947 Common Stock, par value $0.005 per share
INSIDER POWER
233.42
Last 41 transactions
Buy: 2 334 196 | Sell: 10 000

Forecast: 16:00 - $3.48

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $3.48
Forecast 2: 16:00 - $3.48
Forecast 3: 16:00 - $3.48
SCORE
3.43
Buy
Score Algorithm Version: 0.9L
Last version updated: Wed 21th July 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $3.48 (0.87% )
Volume 0.145 mill
Avg. Vol. 0.204 mill
% of Avg. Vol 70.81 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Statera Biopharma, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Statera Biopharma, Inc.

RSI

Intraday RSI14 chart for Statera Biopharma, Inc.
The Live Chart for Statera Biopharma, Inc.
Profile picture for
            Statera Biopharma, Inc.

STAB

Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.

Last 10 Buy Signals
Date Signal @
BTCUSDOct 26 - 23:1360 612
DOGEUSDOct 26 - 23:08$0.258
XRPUSDOct 26 - 23:051.113
DOGEUSDOct 26 - 22:50$0.258
BTCUSDOct 26 - 22:3060 576
XRPUSDOct 26 - 21:571.116
BTCUSDOct 26 - 21:5460 607
DOGEUSDOct 26 - 21:12$0.258
BTCUSDOct 26 - 21:0760 705
XRPUSDOct 26 - 20:481.112

Stock Peers

Company Price Change
STAB3.480.87%
0.0000.00%
0.0000.00%
0.0000.00%
0.0000.00%
0.0000.00%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.